Knowledge Graph
Graph explorer
Search resolved entities, walk their edges, and read the sentence behind every one.
Entities25 of 207,987
- large language modeltechnology1,043 mentions
- robotic manipulationmarket824 mentions
- artificial intelligencetechnology739 mentions
- reinforcement learningtechnology491 mentions
- density-functional theorytechnology386 mentions
- Transformertechnology371 mentions
- agentic AItechnology353 mentions
- vision-language-action modeltechnology350 mentions
- U.S. Food and Drug Administrationorganization320 mentions
- Vision-Language Modeltechnology318 mentions
- Microsoftorganization291 mentions
- Googleorganization276 mentions
- NVIDIAorganization264 mentions
- Model Context Protocoltechnology232 mentions
- machine learningtechnology204 mentions
- MarketsandMarketsorganization199 mentions
- Claudeproduct192 mentions
- AI agenttechnology188 mentions
- ChatGPTproduct178 mentions
- Anthropicorganization177 mentions
- integrated sensing and communicationtechnology175 mentions
- Amazon Web Services, Inc.organization174 mentions
- OpenAIorganization172 mentions
- diffusion modeltechnology169 mentions
- IBMorganization163 mentions
Entity
Atebrioz
product2 mentionslast seen Oct 26, 2026
Oral ALK2 inhibitor for reducing heterotopic ossification in fibrodysplasia ossificans progressiva patients.
Relationships 7
- Atebriozdepends onactivin receptor-like kinase 2 inhibitor99% confidence2 sources
- Atebriozapplies tofibrodysplasia ossificans progressiva treatment99% confidence2 sources
- U.S. Food and Drug AdministrationapprovesAtebrioz98% confidence1 source
- IncytedevelopsAtebrioz97% confidence1 source
- U.S. Food and Drug AdministrationapprovesAtebrioz96% confidence1 source
- Mirum Pharmaceuticals, Inc.commercializesAtebrioz96% confidence1 source
- Mirum Pharmaceuticals, Inc.developsAtebrioz95% confidence1 source
Relationship
Atebriozdepends onactivin receptor-like kinase 2 inhibitor
99% confidence2 supporting mentions
Either name opens that entity’s relationships.
Sources 2
- filingSEC EDGAROct 26, 2026Mirum Pharmaceuticals, Inc. 8-K: Item 8.01: Other Events
ATEBRIOZ (zilurgisertib), an oral activin receptor-like kinase 2 inhibitor
- filingSEC EDGARSep 28, 2026Mirum Pharmaceuticals, Inc. 8-K: Item 8.01: Other Events
a once-daily oral activin receptor-like kinase 2 ("ALK2") inhibitor designed to target the disease-driving pathway